LENSAR Inc., an Orlando, FL-based developer of a laser system for refractive laser-assisted cataract surgery (ReLACS), closed an $87m financing.
This included a $27m private equity financing and up to $60m in debt financing. New investor PDL BioPharma (NASDAQ: PDLI) is providing the credit agreement while Aisling Capital, Florida Growth and Florida Opportunity Funds participated in the equity round.
The company intends to use the funds for its long-term growth and continued commercialization of its
the LENSAR Laser System throughout North America, Europe, Asia, Latin America and select markets worldwide, as well as to develop its hardware and software driven platform.
Led by CEO Nick Curtis, LENSAR develops and commercializes the LENSAR Laser System, an intelligent solution for refractive laser-assisted cataract surgery. Its Augmented Reality technology provides a 3-D model of the eye’s anterior anatomy, resulting in customized treatment and precise placement of every laser pulse.